The board of directors of the Company (the “Board”) is pleased to announce that the pre-application for clinical trials for the Group’s absorbed tetanus vaccine has been submitted recently. The research and development of the vaccine is in line with the Company’s strategic layout in product research and development and is an important step to realize the Company’s research and development of multidisease and multivalent products, which will further improve the Company’s product pipelines, help the Company consolidate its industry position in the field of vaccines not covered by the immunization programs (Class II vaccine) in China, and contribute to the sustainable development of the Company’s vaccine business.

The board of directors of the Company (the “Board”) is pleased to announce that on March 2, 2024, the randomized, blinded and comparable vaccine-controlled Phase II clinical trial of the Group’s tetravalent meningococcal conjugate vaccine (MCV4) was officially initiated, with the Yunnan Provincial Center for Disease Control and Prevention as the responsible institution, and the Center for Disease Control and Prevention of Longyang District, Baoshan and the Center for Disease Control and Prevention of Weishan Yi and Hui Autonomous County, Dali Prefecture as the research sites.

Following its established corporate strategy, the Group proactively advances the development of its vaccine pipelines and accelerates the research and development of the iterative rabies series vaccines through on-going technological innovation, achieving new productive forces at an accelerated pace. As the second largest supplier of rabies vaccine globally, the Group has expedited the development of iterative rabies series vaccines, in particular: 1. the on-site work of the phase III clinical trial of iterative serum-free rabies vaccine has been completed, and various preparatory work for the new drug application is underway, which is planned to be completed in 2024; 2. the pre-application for clinical trial for the novel-process human diploid rabies vaccine is expected to be submitted in the first half of 2024; 3. the iterative mRNA rabies vaccine is the first non-COVID-19 mRNA vaccine candidate accepted by relevant authorities in China.

Following its established corporate strategy, the Group proactively advances the development of its vaccine pipelines and accelerates the research and development of iterative pneumonia series vaccines through on-going technological innovation, achieving new productive forces at an accelerated pace. Leveraging the advantages of its polysaccharide conjugate vaccine technology platform, the Group has developed a series of pneumonia vaccines, including: 1. the 13-valent pneumonia conjugate vaccine has completed on-site work for Phase III clinical trial and has submitted a pre-application for marketing; 2. the 23-valent pneumonia polysaccharide vaccine has also completed Phase III clinical trial and is expected to apply for marketing registration in 2024; 3. the 20-valent pneumonia conjugate vaccine has submitted a pre-application for clinical trials; 4. the 24-valent pneumonia conjugate vaccine, which is being simultaneously developed globally for the first time, has completed preclinical research.

The board of directors of the Company (the “Board”) is pleased to announce that the on-site work of phase III clinical trials for 13-valent pneumonia conjugate vaccine, iterative serum-free rabies vaccine and 23-valent pneumonia polysaccharide vaccine developed by the Group has been completed. The Group is making preparations for the application for marketing of new drugs, and intends to complete the application for marketing in 2024. In addition, the Group has completed the construction of production workshops for the above three vaccines, and completed the production of samples for phase III clinical trials in the completed production workshops.

The board of directors of the Company (the “Board”) is pleased to announce that on 29 February 2024, the Group has submitted the pre-application for marketing registration for its 13-valent pneumonia conjugate vaccine, and plans to officially complete the application for marketing this year.

On December 27, Aimei Vaccine announced that it held an investor open day event on December 22. Almost 40 investment institutions, including CITIC Securities, CITIC Construction Investment Securities, Guotai Junan Securities, and CMB International Securities, visited and toured Aimei's bacterial vaccine industrialization base and mRNA and viral vaccine industrialization production base in Ningbo. They engaged in on-site visits, discussions, and exchanges, gaining detailed insight into the upcoming innovative vaccine products slated for market launch and their production workshop construction, as well as understanding the layout and development plans of the company's product pipeline.

Aimei Vaccine took a significant and important step toward "responding to the WHO's action to eliminate the threat of viral hepatitis by 2030." On December 6, Aimei Vaccine formally entered into a strategic cooperation agreement with the China Foundation for Viral Hepatitis (hereinafter referred to as "the Foundation") to jointly promote the elimination of hepatitis threats in China.

In line with the November quarterly index review announced by MSCI, Aimei Vaccine (06660) was selected as a component stock of the MSCI Global Small Cap Index, with the adjustment taking effect after the market close on November 30.